Abstract: The invention describes the preparation of non-infectious control cells from normal, non-infectious, non-disease altered blood by depletion or augmentation of one or more cell types found in normal blood to reflect a specific disease state. The control cells so produced are preserved and thereafter reconstituted for use in immunological assays.

Abstract: A method for preparing phycobiliprotein/amine-reactive dye conjugates is disclosed in which the conjugates so prepared overcome the energy transfer/fluorescent quenching dilemma encountered in the use of prior art conjugates. A phycobiliprotein, for example, phycoerythrin or allophycocyanin, is conjugated with an amine-reactive dye, for example, Texas Red or carboxyfluorescein succinimidyl ester, in the presence of a selective salt which causes a hydrophobic intramolecular rearrangement of the phycobiliprotein thereby exposing more hydrophobic sites for binding to the amine-reactive dye. The conjugates prepared according to the invention are useful in multiple color fluorescence assays without requiring the use of multiple exciting sources.

Abstract: A single filtration device containing coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The filter device will remove up to about 98% of the endotoxins in addition to removing viruses with an efficiency of at least 4.6.times.10.sup.5 and DNA to less than 10 picograms per 500 mg sample.

Abstract: A hybrid cell line is developed which produces a monoclonal antibody which binds to a unique antigenic site expressed on the surface of phagocytic cells. The monoclonal antibody binds to and activates a specific domain of the CD11b glycoprotein so as to inhibit adhesion dependent functions of the phagocytic cell, but it does not affect other phagocytic functions. This monoclonal antibody can be used as a reactant in an in vitro diagnostic immunoassay for detecting the unique antigenic site on the surface of normal human neutrophils.

Abstract: A control slide for use in an immunoassay having a section of a cell pellet retained on the slide in a stable and substantially permanent formation which can be stored at room temperature. Further, the invention includes the method of making the control slide.

Abstract: A method for preparing a phycobiliprotein-Texas Red conjugate which overcomes the energy transfer/fluorescent quenching dilemma is disclosed. A phycobiliprotein, such as phycoerythrin, is conjugated with dye, such as Texas Red, in the presence of a selective salt which causes a hydrophobic intramolecular rearrangement of the phycobiliprotein thereby exposing more hydrophobic sites for binding to Texas Red. The conjugate is useful in multiple color fluorescence assays without requiring the use of multiple exciting sources.

Abstract: The invention relates generally to colloidal particles having a crosslinked coating with pendent functional groups attached thereto. Magnetic and non-magnetic particles have a biodegradable, crosslinked gelatin coating to which is covalently attached pendent biological substances or molecules, especially monoclonal antibodies. The monoclonal antibodies so attached are useful in a variety of positive and negative biological assays.

Abstract: An antibody-enzyme conjugate is prepared having an enzyme to antibody ratio of approximately 3. The conjugate is produced by adding sulfhydryl groups to an antibody and maleimidyl groups to an enzyme to produce a modified antibody and enzyme, and reacting the modified antibody and enzyme to produce the conjugate. In producing the modified antibody and enzyme, about a 15 molar excess of reagents for introducing sulfhydryl and maleimidyl groups is used. When reacting the modified antibody and enzyme, a four molar excess of the modified enzyme is used, and reacting is stopped after a specified period of time by addition of selective reagents. The selective reagents may be cysteine and iodoacetamide.

Abstract: A hybrid cell line is provided which is capable of producing monoclonal antibodies which binds to HTLV-I and HTLV-II core antigens p24 and p53; but does not bind the p19 core antigen. The antibody also binds to core antigens of simian T-cell leukemia virus Type I (STLV-I). The monoclonal antibody is identified as the KC-88 monoclonal antibody. The cell line which produces the KC-88 monoclonal antibody has been deposited in the American Type Culture Collection, Rockville, Md. and assigned A.T.C.C. Deposit No. HB 10562.

Abstract: A monoclonal antibody which binds preferentially to a subset of the human CD4+ lymphocyte population whereby to positively and precisely distinguish between helper-inducer and suppressor-inducer cells in the CD4+ cell population. The monoclonal antibody recognizes a novel antigen on the CD4+ lymphocytes by means of which it can bind CD4+ cells which express the antigen on the surface of CD4+ cells. The CD4+ subset cell population to which this antibody preferentially binds is the CD4+ helper-inducer population. This selectivity of the monoclonal antibody enables cell sorting, diagnostic and possible therapeutic applications thereof to be realized. The monoclonal antibody also reacts with CD8 cells, B cells and macrophages.

Abstract: A hybridoma cell line is provided which is capable of producing monoclonal antibodies which bind to a unique determinant site on the surface and/or in the cytoplasm of human breast carcinoma cells and carcinoma cells of other adenocarcinomas and on the surface of normal human breast epithelial cells. The cell line of the invention was developed by immunizing mice with a select group of immunogens and a conventional myeloma cell line for fusion with the murine splenocytes harvested.The monoclonal antibody is identified as the BrE2 monoclonal antibody. The antigen is characterized as a high molecular weight glycoprotein complex having a molecular exceeding 400,000 daltons. This monoclonal antibody is especially useful for diagnostic, prognostic and therapeutic applications in human breast cell carcinoma.

Abstract: A single filtration device containing coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The filter device will remove viruses, as modeled by type-C Xenotropic retrovirus, with an efficiency of at least 4.6.times.10.sup.5 ; remove DNA from levels of 10 .mu.g/sample to levels below 10 picograms per 500 mg sample of monoclonal antibody; and will remove at least 97% of some bacterial endotoxins.

Abstract: A hybridoma cell line is provided which is capable of producing a monoclonal antibody which binds to a unique determinant site on the surface and in the cytoplasm of human breast carcinoma cells and cells of other adenocarcinomas and does not bind selectively to the surface of normal breast epithelial cells except in instances of high concentration of the antibody in the testing fluid. The cell line of the invention was developed by immunizing mice with a select group of immunogens and a conventional myeloma cell line for fusion with the murine splenocytes harvested. The monoclonal antibody is identified as the BrE3 monoclonal antibody. The BrE3 monoclonal antibody binds to an antigen which is characterized as a high molecular weight glycoprotein complex having a molecular weight exceeding 400,000 daltons that is bound by a disulfide to a protein of 69,000 daltons.

Abstract: A method is described for the preparation of uniform colloidal particles of ferrites, containing manganese (II), zinc(II), barium(II), iron(II), cobalt(II), or nickel(II), or a mixture of manganese(II) and zinc(II), at a relatively low temperature in the presence of a gelatin solution which acts as a support vehicle for the nucleation and growth of colloidal particles of metal oxide and for dispersion as separate single particles.

Abstract: A method of lyophilizing mammalian cells to produce preserved human cells, hybridoma cell lines, tissue cells, and control cells for immunoassays and other hematological measurements. Prior to freezing and lyophilizing, the prepared mammalian cell pellet is suspended in a solution of trehalose in an isotonic fluid prepared at a specified optimal concentration and incubated at room temperature for a designated time period. The lyophilized cells when rehydrated, retain their optimal physiological characteristics suitable for use as an analytical control and retain said characteristics after storage at 2.degree.-8.degree. C. for a period in excess of five (5) months.

Abstract: An image reversal process for the production of electrophotographic color proofs from negative separation films where the photoconductive recording member is reusable and the proofs are produced on printing stock paper and which very closely match the appearance of the printed sheet.

Abstract: A process for producing a reversed image proof from a negative film separation (66) including applying a uniform toner layer (60) to an offset member (46), exposing a charged surface (20) through the film separation (66) to produce unexposed non-image areas (68) and exposed image areas (70) thereon, contacting the offset member (46) to the charged surface (20) to transfer toner (74) from the offset member (46) to the surface (20) in the non-image areas (68), leaving an image residue (76) upon the offset member (46), and contacting the offset member (46) to a receptor (49) to transfer the image (76) thereto. The process may be repeated for subsequent colors to produce a positive multicolor image and may also be adapted to conventional proofers formerly capable of producing images from positive film separations only.

Abstract: A hybrid cell line is developed which produces a monoclonal antibody which binds to a unique antigenic site expressed on the surface of phagocytic cells. The monoclonal antibody binds to and activates a specific domain of the CD11b glycoprotein so as to inhibit adhesion dependent functions of the phagocytic cell, but it does not affect other phagocytic functions. This monoclonal antibody can be used as a reactant in an in vitro diagnostic immunoassay for detecting the unique antigenic site on the surface of normal human neutrophils.

Abstract: A monoclonal antibody which binds preferentially to a subset of the human CD8 lymphocyte population whereby to positively and precisely distinguish between cytotoxic effector and supressor effector cells in the CD8 cell population. The monoclonal antibody recognizes a novel epitope of LFA-1 antigen by means of which it can bind CD8 cells which express the eptope on a surface antigen thereof. The CD8 subset cell population to which this anitbody binds preferentially is the CD8 cytotoxic effector population. This selectivity of the monoclonal antibody enables cell sorting, diagnostic and positive therapeutic applications thereof to be utilized.

Abstract: Murine monoclonal antibodies specific to unique antigenic determinants on mammalian terminal deoxynucleotidyl transferases (TdT). The monoclonal antibodies specifically bind to TdT in a wide variety of mammalian cells including human, mouse, rat, rabbit and bovine origin. The monoclonal antibodies are secreted by hybridoma cell lines derived from fusion of murine plasmacytoma cells with splenocytes from mice immunized with TdT from bovine thymus cells. The monoclonal antibodies can detect small numbers of TdT-positive cells from monitoring of TdT-positive leukemias and lymphomas in multple species, including human.